ITRM

Iterum Therapeutics plc [ITRM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ITRM Stock Summary

Top 10 Correlated ETFs

ITRM


Top 10 Correlated Stocks

ITRM


In the News

04:30 29 Mar 2024 ITRM

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Thursday, March 28, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.

09:00 29 Mar 2024 ITRM

Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up

Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.

08:30 29 Mar 2024 ITRM

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023

DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, November 14, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.

09:15 29 Mar 2024 ITRM

Iterum Therapeutics to Present Data at IDWeek 2023

DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America's IDWeek 2023 conference taking place in Boston, MA from October 11-15, 2023.

05:00 29 Mar 2024 ITRM

Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023

DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Friday, August 11, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.

06:23 29 Mar 2024 ITRM

Iterum Therapeutics to Present Data at ASM Microbe 2023

DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference.

01:39 29 Mar 2024 ITRM

All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy

Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

05:00 29 Mar 2024 ITRM

Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.

11:42 29 Mar 2024 ITRM

Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript

Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief Executive Officer Judy Matthews – Chief Financial Officer Conference Call Participants Ed Acre – H.C. Wainwright Operator Ladies and gentlemen, welcome to the Iterum Therapeutics Third Quarter 2022 Financial Results Call.

05:19 29 Mar 2024 ITRM

Iterum Therapeutics to Present Data at IDWeek 2022

DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America's IDWeek 2022.

ITRM Financial details

Company Rating
Neutral
Market Cap
21.47M
Income
-31.1M
Revenue
0
Book val./share
0.26
Cash/share
2.75
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-0.91
Forward P/E
-1.18
PEG
0.13
P/S
-
P/B
8.28
P/C
0.56
P/FCF
-0.95
Quick Ratio
2.2
Current Ratio
2.35
Debt / Equity
5.8
LT Debt / Equity
5.71
-
-
EPS (TTM)
-2.44
EPS next Y
-1.31
EPS next Q
-0.88
EPS this Y
-56.84%
EPS next Y
-46.52%
EPS next 5Y
-84.02%
EPS last 5Y
-51.29%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-68.42%
-
-
-
-
SMA20
19.55%
SMA50
-19.29%
SMA100
130.43%
Inst Own
0%
Inst Trans
0.98%
ROA
-78%
ROE
-216%
ROC
-1.88%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
13.42M
Shs Float
13.08M
-
-
-
-
Target Price
-
52W Range
0.622-2.5
52W High
-
52W Low
-
RSI
50.49
Rel Volume
0.36
Avg Volume
629K
Volume
228.46K
Perf Week
-6.67%
Perf Month
4.05%
Perf Quarter
113.8%
Perf Half Y
126.47%
-
-
-
-
Beta
2.348
-
-
Volatility
0.02%, 0.13%
Prev Close
-3.14%
Price
1.54
Change
-4.35%

ITRM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.490.04000
Net income per share
-132.34-106.55-32.49-8.41-3.63
Operating cash flow per share
-130.33-81.5-34.07-1.45-1.51
Free cash flow per share
-130.49-81.53-34.07-1.46-1.51
Cash per share
145.214.9610.547.474.97
Book value per share
123-27.11-31.594.612.29
Tangible book value per share
123-27.11-31.594.32.15
Share holders equity per share
123-27.11-31.594.612.29
Interest debt per share
24.9414.7635.882.952.55
Market cap
43.76M65.33M23.75M64.04M10.28M
Enterprise value
12.29M68.16M45.1M61.49M17.65M
P/E ratio
-0.57-0.63-0.46-0.7-0.23
Price to sales ratio
50.351.77K000
POCF ratio
-0.58-0.83-0.44-4.04-0.56
PFCF ratio
-0.58-0.83-0.44-4.03-0.55
P/B Ratio
0.61-2.49-0.471.270.37
PTB ratio
0.61-2.49-0.471.270.37
EV to sales
14.141.84K000
Enterprise value over EBITDA
-0.16-0.67-1.3-2.53-0.49
EV to operating cash flow
-0.16-0.86-0.83-3.88-0.96
EV to free cash flow
-0.16-0.86-0.83-3.87-0.95
Earnings yield
-1.76-1.58-2.19-1.43-4.32
Free cash flow yield
-1.74-1.21-2.3-0.25-1.8
Debt to equity
0.2-0.51-0.840.531.03
Debt to assets
0.140.521.290.290.43
Net debt to EBITDA
0.41-0.03-0.610.1-0.21
Current ratio
6.930.130.513.43310.4
Interest coverage
-179.72-118.49-2.13-4.42-12.87
Income quality
0.980.761.050.170.42
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
10.1304.97000
Research and developement to revenue
792.45K000
Intangibles to total assets
0000.040.03
Capex to operating cash flow
00000
Capex to revenue
-0.1-0.65000
Capex to depreciation
-0.66-0.16-0.07-0.03-0.03
Stock based compensation to revenue
1.4858.73000
Graham number
605.19254.94151.9629.5413.67
ROIC
-0.916.8910.69-0.31-0.53
Return on tangible assets
-0.79-4-1.59-1.04-0.68
Graham Net
94.3-52.04-42.33.621.75
Working capital
72.45M-32.19M-14.36M75.29M60.64M
Tangible asset value
71.62M-26.24M-50.56M46.8M26.28M
Net current asset value
58.42M-47.19M-68.84M40.07M22M
Invested capital
0.2-0.51-0.840.531.03
Average receivables
615K916K988K1.04M859K
Average payables
3.6M9.76M8.15M847K1.83M
Average inventory
-3.93M-7.95M-5.88M-3.43M-2.49M
Days sales outstanding
302.8410.96K000
Days payables outstanding
001.85K152.31562.51
Days of inventory on hand
00-8.48K-542.47-375.34
Receivables turnover
1.210.03000
Payables turnover
000.22.40.65
Inventory turnover
00-0.04-0.67-0.97
ROE
-1.083.931.03-1.82-1.59
Capex per share
-0.15-0.02-0.01-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.38-0.41-0.78-0.95-0.3
Operating cash flow per share
-0.37-0.35-0.76-0.59-0.71
Free cash flow per share
-0.37-0.35-0.76-0.59-0.71
Cash per share
5.264.954.093.462.75
Book value per share
2.662.281.490.550.26
Tangible book value per share
2.492.141.390.480.26
Share holders equity per share
2.662.281.490.550.26
Interest debt per share
2.552.342.432.521.55
Market cap
19.82M10.33M12.68M13.85M10.44M
Enterprise value
29.54M17.7M25.99M32.03M25.22M
P/E ratio
-0.17-0.51-0.32-0.28-0.67
Price to sales ratio
00000
POCF ratio
-4.37-2.42-1.32-1.81-1.13
PFCF ratio
-4.36-2.4-1.32-1.81-1.13
P/B Ratio
0.610.370.671.943.04
PTB ratio
0.610.370.671.943.04
EV to sales
00000
Enterprise value over EBITDA
-1.24-1.63-3.23-3.1-1.56
EV to operating cash flow
-6.51-4.15-2.71-4.2-2.72
EV to free cash flow
-6.5-4.11-2.71-4.19-2.72
Earnings yield
-1.47-0.49-0.78-0.88-0.37
Free cash flow yield
-0.23-0.42-0.76-0.55-0.89
Debt to equity
0.941.031.614.535.8
Debt to assets
0.430.430.520.630.5
Net debt to EBITDA
-0.41-0.68-1.65-1.76-0.91
Current ratio
8.88310.46.964.42.35
Interest coverage
-11.0699.08-21.38-33.4-55.62
Income quality
0.160.840.970.622.39
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.030.030.020.020.01
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
-0.02-0.10-0.040.01
Stock based compensation to revenue
00000
Graham number
11.944.615.123.421.33
ROIC
-0.11-0.14-0.17-0.27-0.74
Return on tangible assets
-0.42-0.08-0.17-0.24-0.1
Graham Net
2.121.7510.07-0.02
Working capital
59.14M60.64M46.45M36.82M22.13M
Tangible asset value
30.4M26.28M17.67M6.27M3M
Net current asset value
27.65M22M15.08M3.76M2.23M
Invested capital
0.941.031.614.535.8
Average receivables
621.5K654K410.5K217.5K148.5K
Average payables
1.01M2M2.5M2.98M4.61M
Average inventory
0-925.5K-1.08M-217.5K-63.5K
Days sales outstanding
00000
Days payables outstanding
246.9568.7461.35763.361.14K
Days of inventory on hand
0-379.48-63.58-26.10
Receivables turnover
00000
Payables turnover
0.360.160.20.120.08
Inventory turnover
0-0.24-1.42-3.450
ROE
-0.89-0.18-0.52-1.72-1.13
Capex per share
00000

ITRM Frequently Asked Questions

What is Iterum Therapeutics plc stock symbol ?

Iterum Therapeutics plc is a IE stock and trading under the symbol ITRM

What is Iterum Therapeutics plc stock quote today ?

Iterum Therapeutics plc stock price is $1.54 today.

Is Iterum Therapeutics plc stock public?

Yes, Iterum Therapeutics plc is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap